Compare KSCP & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSCP | RANI |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.7M | 134.6M |
| IPO Year | 2022 | 2021 |
| Metric | KSCP | RANI |
|---|---|---|
| Price | $4.82 | $1.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $16.67 | $8.67 |
| AVG Volume (30 Days) | 365.4K | ★ 2.6M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,610,000.00 | $1,200,000.00 |
| Revenue This Year | $8.68 | $414.59 |
| Revenue Next Year | $32.17 | $30.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.50 | N/A |
| 52 Week Low | $2.45 | $0.39 |
| 52 Week High | $17.79 | $3.87 |
| Indicator | KSCP | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 40.73 |
| Support Level | $4.35 | $1.52 |
| Resistance Level | $5.06 | $1.67 |
| Average True Range (ATR) | 0.33 | 0.13 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 43.16 | 3.04 |
Knightscope Inc is a security technology company based in Silicon Valley. It designs, develops, manufactures, markets, and supports Autonomous Security Robots (ASRs), autonomous charging stations, the proprietary Knightscope Security Operations Center software user interface, Emergency Communication Devices platform with real-time on-site data collection and analysis and a proprietary interface for both indoor and outdoor usage. In addition, it developed and operates the Knightscope Security Operations Center (KSOC) which allows real-time data access, a service accessible to all its clients.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.